Malgorzata Misiewicz
Overview
Explore the profile of Malgorzata Misiewicz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mikulski D, Koscielny K, Drozdz I, Nowicki M, Misiewicz M, Perdas E, et al.
Infect Chemother
. 2024 Aug;
56(3):339-350.
PMID: 39098001
Background: Autologous hematopoietic stem cell transplantation (AHSCT) is currently the backbone of the treatment of multiple myeloma (MM) and relapsed and refractory lymphomas. Notably, infections contribute to over 25% of...
2.
Mikulski D, Koscielny K, Drozdz I, Mirocha G, Nowicki M, Misiewicz M, et al.
Int J Mol Sci
. 2024 Apr;
25(8).
PMID: 38673940
Hepatic complications are an acknowledged cause of mortality and morbidity among patients undergoing hematopoietic stem cell transplantation. In this study, we aimed to evaluate the potential role in the prediction...
3.
Mikulski D, Nowicki M, Drozdz I, Perdas E, Strzalka P, Koscielny K, et al.
Biomark Res
. 2024 Apr;
12(1):42.
PMID: 38650024
Autologous hematopoietic stem cell transplantation (AHSCT) remains the most prevalent type of stem cell transplantation. In our study, we investigated the changes in circulating miRNAs in AHSCT recipients and their...
4.
Koscielny K, Mikulski D, Nowicki M, Wyka K, Misiewicz M, Perdas E, et al.
Transpl Infect Dis
. 2023 Dec;
26(1):e14212.
PMID: 38112043
Infectious complications of autologous hematopoietic stem cell transplantation (AHSCT) are the most common adverse effects of the therapy, resulting in prolonged hospitalization and deterioration of patient well-being. Identifying predictors of...
5.
Pula A, Robak T, Drozdz I, Stawiski K, Rycerz A, Misiewicz M, et al.
Leuk Lymphoma
. 2023 Nov;
65(2):257-264.
PMID: 37948578
Despite advances in multiple myeloma (MM) treatment, drug resistance remains a clinical challenge. We aimed to develop a prognostic model for bortezomib resistance based on miRNA expression profiling. The study...
6.
Mikulski D, Nowicki M, Drozdz I, Misiewicz M, Koscielny K, Okonski K, et al.
Front Oncol
. 2023 Oct;
13:1250355.
PMID: 37829335
Introduction: AHSCT is the treatment of choice for newly diagnosed patients with transplant-eligible multiple myeloma (MM). However, considerable variability in response to autologous hematopoietic stem cell transplantation (AHSCT) results in...
7.
Pula A, Robak P, Jarych D, Mikulski D, Misiewicz M, Drozdz I, et al.
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36769265
Multiple myeloma (MM) is a hematological malignancy characterized by the clonal proliferation of plasma cells in the bone marrow (BM) microenvironment. Despite the progress made in treatment, some MM patients...
8.
Mikulski D, Robak P, Perdas E, Weglowska E, Losiewicz A, Drozdz I, et al.
J Clin Med
. 2022 Jan;
11(1).
PMID: 35011853
Multiple myeloma (MM) is characterized by the malignant proliferation of monoclonal plasma cells in the bone marrow with an elevation in monoclonal paraprotein, renal impairment, hypercalcemia, lytic bony lesions, and...
9.
Robak P, Szemraj J, Mikulski D, Drozdz I, Juszczak K, Jarych D, et al.
J Clin Med
. 2021 Nov;
10(21).
PMID: 34768548
While multiple myeloma (MM) treatment with proteasome inhibitors and other agents yields encouraging results, primary and secondary resistance remains an emerging problem. An important factor in such treatment resistance is...
10.
Robak P, Jarych D, Mikulski D, Drozdz I, Weglowska E, Kotkowska A, et al.
Cancers (Basel)
. 2021 Mar;
13(5).
PMID: 33668794
Proteasome inhibitors, like bortezomib, play a key role in the treatment of multiple myeloma (MM); however, most patients eventually relapse and eventually show multiple drug resistance, and the molecular mechanisms...